Evidence map›Paper›PMID 39205296›Full record

ArticleViruses2024

Nifuroxazide Prevents Chikungunya Virus Infection Both

Yangang Liu, Mingxiao Xu, Binghui Xia, Zhuoyue Qiao, Yanhua He, Yan Liu, Zhendong Pan, Congcong Zhang, Haoran Peng, Xuesong Liang and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Viruses, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Trial
  2. Article
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Yangang LiuDepartment of Microbiology, Faculty of Naval Medicine, Naval Medical University, Shanghai 200433, China.
Mingxiao XuDepartment of Infection Diseases, First Affiliated Hospital of Navy Military Medical University, Shanghai 200433, China.
Binghui XiaDepartment of Microbiology, Faculty of Naval Medicine, Naval Medical University, Shanghai 200433, China.
Zhuoyue QiaoKey Laboratory of Chemistry in Ethnic Medicinal Resources, State Ethnic Affairs Commission & Ministry of Education, Yunnan Minzu University, Kunming 650500, China.
Yanhua HeDepartment of Microbiology, Faculty of Naval Medicine, Naval Medical University, Shanghai 200433, China.
Yan LiuDepartment of Microbiology, Faculty of Naval Medicine, Naval Medical University, Shanghai 200433, China.
Zhendong PanDepartment of Microbiology, Faculty of Naval Medicine, Naval Medical University, Shanghai 200433, China.
Congcong ZhangDepartment of Microbiology, Faculty of Naval Medicine, Naval Medical University, Shanghai 200433, China.
Haoran PengDepartment of Microbiology, Faculty of Naval Medicine, Naval Medical University, Shanghai 200433, China.
Xuesong LiangDepartment of Infection Diseases, First Affiliated Hospital of Navy Military Medical University, Shanghai 200433, China.
Ping ZhaoDepartment of Microbiology, Faculty of Naval Medicine, Naval Medical University, Shanghai 200433, China.
Hailin TangDepartment of Microbiology, Faculty of Naval Medicine, Naval Medical University, Shanghai 200433, China.ORCID 0000-0002-4090-8852
Xu ZhengDepartment of Microbiology, Faculty of Naval Medicine, Naval Medical University, Shanghai 200433, China.ORCID 0009-0004-9859-1909

Funding

National Natural Science Foundation of China 32100122Shanghai Sailing Program 21YF1457800
6 · The paper itself

Abstract

Chikungunya virus (CHIKV) is a reemerging arbovirus causing disease on a global scale, and the potential for its epidemics remains high. CHIKV has caused millions of cases and heavy economic burdens around the world, while there are no available approved antiviral therapies to date. In this study, nifuroxazide, an FDA-approved antibiotic for acute diarrhea or colitis, was found to significantly inhibit a variety of arboviruses, although its antiviral activity varied among different target cell types. Nifuroxazide exhibited relatively high inhibitory efficiency in yellow fever virus (YFV) infection of the hepatoma cell line Huh7, tick-borne encephalitis virus (TBEV) and west nile virus (WNV) infection of the vascular endothelial cell line HUVEC, and CHIKV infection of both Huh7 cells and HUVECs, while it barely affected the viral invasion of neurons. Further systematic studies on the action stage of nifuroxazide showed that nifuroxazide mainly inhibited in the viral replication stage.

Indexed as

Antiviral AgentsChikungunya FeverChikungunya virusHydroxybenzoatesNitrofuransVirus ReplicationAnimalsCell LineHumansHuman Umbilical Vein Endothelial CellsMiceViral LoadAntiviral AgentsHydroxybenzoatesnifuroxazideNitrofuransantiviral drugarbovirusesChikungunya virusnifuroxazideviral replication

Identifiers

PMID39205296
PMCPMC11360488

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.